Rafael Amado Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Rafael Amado.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Rafael Amado. Rafael Amado is Chief Medical Officer in Adaptimmune Therapeutics PLC ($ADAP) and President, R & D in Adaptimmune Therapeutics PLC ($ADAP) and President, R&D in Adaptimmune Therapeutics PLC ($ADAP) and EVP of R&D and CMO in Allogene Therapeutics, Inc. ($ALLO).
Latest Insider Trading Transactions of Rafael Amado
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 17 2021 | ALLO | Allogene Therapeut ... | Amado Rafael | EVP of R&D and CMO | Sell | S | 38.05 | 2,798 | 106,471 | 110,035 | 112.8 K to 110 K (-2.48 %) |
| Oct 08 2020 | ALLO | Allogene Therapeut ... | Amado Rafael | EVP of R&D and CMO | Sell | S | 39.40 | 16,538 | 651,515 | 111,677 | 128.2 K to 111.7 K (-12.90 %) |
| Mar 20 2020 | ALLO | Allogene Therapeut ... | Amado Rafael | EVP of R&D and CMO | Option Exercise | A | 18.22 | 109,600 | 1,996,912 | 109,600 | |
| Mar 20 2020 | ALLO | Allogene Therapeut ... | Amado Rafael | EVP of R&D and CMO | Grant | A | 0.00 | 30,800 | 0 | 135,962 | 105.2 K to 136 K (+29.29 %) |
| Sep 05 2019 | ALLO | Allogene Therapeut ... | Amado Rafael | EVP of R&D and CMO | Option Exercise | A | 26.15 | 160,630 | 4,200,475 | 160,630 | |
| Sep 05 2019 | ALLO | Allogene Therapeut ... | Amado Rafael | EVP of R&D and CMO | Grant | A | 0.00 | 105,162 | 0 | 105,162 | 0 to 105.2 K |
| Sep 05 2019 | ALLO | Allogene Therapeut ... | Amado Rafael | EVP of R&D and CMO | Option Exercise | A | 26.15 | 160,630 | 4,200,475 | 160,630 | |
| Sep 05 2019 | ALLO | Allogene Therapeut ... | Amado Rafael | EVP of R&D and CMO | Grant | A | 0.00 | 105,162 | 0 | 105,162 | 0 to 105.2 K |
| Aug 07 2019 | ADAP | Adaptimmune Therap ... | Amado Rafael | President, R&D | Sell | S | 2.06 | 11,043 | 22,749 | 17,237 | 28.3 K to 17.2 K (-39.05 %) |
| Jan 16 2019 | ADAP | Adaptimmune Therap ... | Amado Rafael | President, R & D | Sell | S | 5.37 | 3,028 | 16,259 | 4,974 | 8 K to 5 K (-37.84 %) |
| Jan 08 2019 | ADAP | Adaptimmune Therap ... | Amado Rafael | President, R & D | Option Exercise | A | 0.00 | 224,724 | 292 | 224,724 | |
| Jan 08 2019 | ADAP | Adaptimmune Therap ... | Amado Rafael | President, R & D | Option Exercise | A | 0.00 | 224,724 | 292 | 224,724 | |
| Jan 08 2019 | ADAP | Adaptimmune Therap ... | Amado Rafael | President, R & D | Option Exercise | A | 0.89 | 1,006,224 | 895,539 | 1,006,224 | |
| Jan 08 2019 | ADAP | Adaptimmune Therap ... | Amado Rafael | President, R & D | Option Exercise | A | 0.89 | 1,006,224 | 895,539 | 1,006,224 | |
| Aug 07 2018 | ADAP | Adaptimmune Therap ... | Amado Rafael | President, R & D | Option Exercise | A | 0.00 | 678,720 | 882 | 678,720 | |
| Jan 17 2018 | ADAP | Adaptimmune Therap ... | Amado Rafael | Chief Medical Offic ... | Option Exercise | A | 0.00 | 192,060 | 269 | 192,060 | |
| Jan 17 2018 | ADAP | Adaptimmune Therap ... | Amado Rafael | Chief Medical Offic ... | Option Exercise | A | 1.30 | 859,968 | 1,117,958 | 859,968 | |
| Jan 18 2017 | ADAP | Adaptimmune Therap ... | Amado Rafael | Chief Medical Offic ... | Option Exercise | A | 0.72 | 2,072,976 | 1,492,543 | 2,072,976 | |
| Jan 20 2016 | ADAP | Adaptimmune Therap ... | Amado Rafael | Chief Medical Offic ... | Option Exercise | A | 1.27 | 939,948 | 1,195,332 | 939,948 |
Page: 1